Score
2
2005
pubmed
[The effect of vilon (Lys-Glu) on 1.2-dimethylhydrazine-induced neoplasia].
Pliss. G B GB; Mel'nikov. A S AS; Malinin. V V VV; Khavinson. V Kh VKh
Key Findings
- Vilon at 10 µg/kg reduced tumor incidence from 60% to 14.3% in mice
- The treatment delayed tumor appearance to around 46 weeks
- Vilon also lessened preneoplastic kidney alterations
Practical Outcomes
- The results are interesting but only in mice and use a very specific cancer model, so they don’t translate into a clear human protocol yet. Biohackers should view this as early‑stage evidence of possible anti‑cancer activity, not a ready‑to‑use supplement, and await further safety and dosing studies.
Summary
In a mouse study, giving a tiny amount of the peptide vilon (Lys‑Glu) lowered the chance of getting colon‑type tumors from a cancer‑causing chemical, dropping tumor rates from 60% to about 14%, and also reduced early‑stage kidney changes linked to cancer.
Abstract
The influence of vilon (Lys-Glu) on 1.2-dimethylhydrazine-induced neoplasia in mice has been studied. After treatment with 10 microg/kg, tumors developed in 14.3% which survived until first tumor detection (46 weeks) while, in control group, tumors occurred in 60%. Vilon-related inhibition of preneoplastic alterations in the kidneys was reported.
Study Information
Provider
pubmed
Year
2005